No “easy home runs”: Early Long COVID trials of Paxlovid and monoclonal antibodies failed, but the treatments still have potential

While three early clinical trials of these drugs – including the UCSF outSMART trial – did not find they led to health improvements for participants, further trials are getting more intentional in targeting viral persistence.